Deltagen Inc. (DGEN) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 0.04 means the share price is 0.04 times one year of earnings per share.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerDeltagen Inc. (DGEN) trades at $0.0001. Deltagen Inc. provides drug discovery tools and services to the biopharmaceutical industry, offering biological models and drug targets. Sector: Healthcare.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for DGEN: DGEN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Deltagen Inc. (DGEN) Healthcare & Pipeline Overview
Deltagen Inc. delivers drug discovery tools and services, offering biological models and target validation data to biopharmaceutical companies. Specializing in immunology and metabolic diseases, Deltagen aims to improve drug discovery efficiency. The company operates within the medical instruments and supplies sector, providing crucial resources for pharmaceutical innovation.
What Is the Investment Thesis for DGEN?
Deltagen Inc. operates in the attractive drug discovery tools and services market, benefiting from the increasing R&D spending in the biopharmaceutical industry. With a gross margin of 99.5%, the company demonstrates a strong ability to generate revenue from its services. However, the company's negative profit margin of -6.0% and negative ROE of -2.7% indicate challenges in achieving profitability. The high beta of 76.36 suggests significant volatility relative to the market. Potential catalysts include successful expansion of its target validation data offerings and strategic partnerships with larger pharmaceutical companies. The company's debt-to-equity ratio of 1.46 indicates a moderate level of financial leverage. Investors should closely monitor Deltagen's ability to improve its profitability and manage its financial risks.
Based on FMP financials and quantitative analysis
DGEN Key Highlights
Gross Margin of 99.5% indicates a strong ability to generate revenue from its services.
- Profit Margin of -6.0% reflects challenges in achieving profitability.
- Return on Equity (ROE) of -2.7% suggests inefficient use of equity to generate profits.
- Debt-to-Equity Ratio of 1.46 indicates a moderate level of financial leverage.
- Beta of 76.36 indicates high volatility compared to the market.
Who Are DGEN's Competitors?
DGEN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| GCTK GlucoTrack, Inc. | $1.21 | -14.18% | — | |
| LUCY Innovative Eyewear, Inc. | $0.89 | -3.14% | $5.62M | — |
| FEMY Femasys Inc. | $2.05 | -2.38% | $6.19M | — |
| RGNT Regentis Biomaterials Ltd. | $1.85 | +1.09% | $13.0M | 64 5-pillar |
| MLSS Milestone Scientific Inc. | $0.38 | -7.58% | $33.4M | — |
| HBIO Harvard Bioscience, Inc. | $8.34 | +2.58% | $37.6M | — |
| NEPH Nephros, Inc. | $3.67 | 0.00% | $39.8M | 33 5-pillar |
| POCI Precision Optics Corporation, Inc. | $4.46 | +4.45% | $48.8M | 37 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DGEN's Key Strengths?
Specialized expertise in drug discovery tools and services
- Strong focus on immunology and metabolic diseases
- High gross margin of 99.5%
- Proprietary biological models
What Are DGEN's Weaknesses?
Negative profit margin of -6.0%
- Negative ROE of -2.7%
- High beta of 76.36
- Limited financial resources
What Are the Key Risks for DGEN?
Financial-distress signal — its Altman Z-Score of -44.79 sits in the distress zone (elevated bankruptcy risk).
- Intense competition from larger, more established drug discovery companies.
- Changes in regulatory requirements impacting drug discovery processes and data validation.
- Economic downturn potentially affecting R&D spending in the biopharmaceutical industry.
- Technological advancements rendering current drug discovery tools and services obsolete.
What Are DGEN's Competitive Advantages?
- Proprietary biological models
- Expertise in target validation
- Established relationships with biopharmaceutical companies
What Does DGEN Do?
Deltagen Inc., established in 1999 and headquartered in San Mateo, California, is a key provider of drug discovery tools and services to the biopharmaceutical industry. The company was founded with the mission to accelerate and enhance the drug discovery process. Deltagen offers a comprehensive suite of programs designed to improve the efficiency of drug discovery, including access to a variety of biological models, as well as small-molecule and secreted protein drug targets. These resources enable biopharmaceutical companies to identify and validate potential drug candidates more effectively. Deltagen's core offerings include target validation data, with a particular focus on the areas of immunology and metabolic diseases. By providing high-quality, validated data, Deltagen helps its clients to de-risk their drug discovery efforts and make more informed decisions about which targets to pursue. The company's services are utilized by a range of biopharmaceutical companies, from small startups to large multinational corporations. Deltagen's commitment to innovation and quality has established it as a trusted partner in the drug discovery process.
What Products and Services Does DGEN Offer?
- Provides drug discovery tools to biopharmaceutical companies.
- Offers biological models for drug discovery.
- Provides small-molecule and secreted protein drug targets.
- Offers target validation data in immunology.
- Offers target validation data in metabolic diseases.
- Enhances the efficiency of drug discovery processes.
How Does DGEN Make Money?
- Generates revenue by providing access to biological models.
- Generates revenue by providing small-molecule and secreted protein drug targets.
- Generates revenue by providing target validation data.
- Offers subscription-based access to its drug discovery platform.
What Industry Does DGEN Operate In?
Deltagen Inc. operates within the medical instruments and supplies industry, a segment of the broader healthcare sector. The industry is characterized by continuous innovation and increasing demand for advanced drug discovery tools and services. The biopharmaceutical industry's growing R&D expenditure drives the demand for companies like Deltagen. The competitive landscape includes companies offering similar drug discovery tools and services, requiring Deltagen to differentiate itself through innovation and quality of data. Market trends include a focus on personalized medicine and the development of targeted therapies, which further increases the need for efficient target validation and drug discovery processes.
Who Are DGEN's Key Customers?
- Biopharmaceutical companies
- Pharmaceutical companies
- Drug discovery research institutions
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Deltagen Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in San Mateo, US. The company is led by CEO Robert J. Driscoll. DGEN has traded publicly since 2000.
Key Financial Metrics
Return on equity for Deltagen Inc. stands at 4.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.1%, showing how much profit it generates from its asset base. A current ratio of 2.30 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Deltagen Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -44.79 places it in the distress zone, a signal of elevated financial risk.
DGEN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
DGEN Latest News
No recent news available for DGEN.
DGEN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for DGEN.
Price Targets
Wall Street price target analysis for DGEN.
DGEN MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for DGEN; grades run from A+ (80-100) to F (below 30).
DGEN OTC Market Information
DGEN trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
DGEN Healthcare Stock FAQ
What does Deltagen Inc. do?
Deltagen Inc. provides drug discovery tools and services to the biopharmaceutical industry, focusing on enhancing the efficiency of drug discovery.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- Competitor information is limited due to a lack of specific peer data.